Richard Delorme is head of the Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders (InovAND) and head of the Department of Child and Adolescent Psychiatry at the Robert Debré Hospital, both in Paris, France. He has a broad background in child psychiatry and genetics, with expertise in the identification of biomarkers in rare diseases associated with autism. He is also a researcher at the Human Genetics and Cognitive Functions Laboratory at the Institut Pasteur, in Paris. In recent years, he has been involved in several research programs, brain imaging studies and IPSC-based drug screening technology. He is an author on more than 100 publications.
Richard Delorme
Head
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
By
Richard Delorme, Benjamin Landman
21 April 2020 | 4 min read
Explore more from The Transmitter
Exclusive: Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
Exclusive: Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
By
Calli McMurray
2 October 2025 | 10 min read
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
By
Brendan Borrell
1 October 2025 | 11 min read
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
By
Devin Effinger, Melissa Herman
1 October 2025 | 7 min listen